14 C]viramidine and [ 14 C]ribavirin were compared in rat and monkey red blood cells and liver. Our data reveal that the total ribavirin-related components (ribavirin plus its mono-, di-, and triphosphate metabolites) may account for most of the drug in monkey liver following prolonged oral administration of viramidine.
Ribavirin is a purine nucleoside analog ( Fig. 1 ) with broadspectrum activity against a variety of DNA and RNA viral infections (17, 19) . In combination with either alpha interferon or pegylated alpha interferon, the clinical efficacy of ribavirin in the treatment of chronic hepatitis C virus infection, in terms of a sustained virologic response, has been shown to be about 41 to 47% (13, 16 ) and 54 to 56% (4, 11, 12) , respectively. However, ribavirin had a dose-limiting side effect. After entering the circulation, a significant portion of ribavirin is transported into erythrocytes (RBC) (6) and metabolized into various phosphorylated derivatives (15) . Owing to the lack of phosphatase activity in RBC, these phosphorylated metabolites of ribavirin are trapped intracellularly and accumulate over time, leading to hemolytic anemia (6, 7, 15) . This adverse effect often necessitates dose reduction and discontinuation of ribavirin therapy in a significant proportion of patients. Therefore, a new form of ribavirin that retains ribavirin's clinical efficacy but has less potential for hemolytic anemia would be highly desirable.
Viramidine ( Fig. 1 ) may be converted to ribavirin by adenosine deaminase (21) . In rats and monkeys following oral administration, viramidine was extensively converted to ribavirin, followed by further metabolism to ribofuranosyl triazole carboxylic acid and triazole carboxamide (TCONH 2 ) (8) . Ribavirin has also been reported to undergo metabolism to ribofuranosyl triazole carboxylic acid and TCONH 2 (9) . Despite the lower absorption of viramidine compared to that of ribavirin, the plasma ribavirin AUC after viramidine administration in rats was similar to or slightly higher than the plasma ribavirin AUC after ribavirin administration (8, 9) . This is in good agreement with the rapid conversion of viramidine to ribavirin in rats. In monkeys, however, the plasma ribavirin AUC following viramidine administration was lower than the plasma ribavirin AUC following ribavirin administration. This is probably related to either lower absorption of viramidine compared to that of ribavirin in monkeys and/or the slower rate of conversion of viramidine to ribavirin (8, 9 RBC samples were solubilized with Solvable (Packard Instruments) and then decolorized with hydrogen peroxide. The mixtures were then neutralized with 0.5 N hydrochloric acid and measured for radioactivity by liquid scintillation counting. Liver samples were solubilized in 2 M potassium hydroxide at 50°C for 9 days. After cooling, the samples were decolorized with hydrogen peroxide, followed by 2 h of incubation at room temperature. The mixtures were then neutralized with 0.5 N hydrochloric acid, and the radioactivity was determined by liquid scintillation counting.
EDTA solution (0.5 M) was added to RBC samples, and the mixture was vortexed for 10 s. Deionized water and methanol were added to the sample, and the mixture was vortexed and centrifuged. The supernatant was collected. A portion of liver (1 g) and 3 ml of cold perchloric acid (3.5%) were homogenized and centrifuged. The supernatant was neutralized with 10 N ammonium hydroxide to a pH of 6 to 7. All RBC and liver extracts were stored at Ϫ80°C.
The NH 2 cartridge was preconditioned with 1.0 ml of water. An aliquot of liver or RBC extracts was premixed with water and loaded onto the cartridge. The eluant was collected, and this fraction contained ribavirin, viramidine, and TCONH 2 . The fraction containing monophosphates was eluted with 2.0 ml of 100 mM ammonium phosphate-acetonitrile (80/20, vol/ vol). The column was then rinsed with 2.0 ml of 300 mM ammonium phosphate-acetonitrile (80/20, vol/vol) to collect diphosphates. Finally, triphosphates were eluted with 2.0 ml of 400 mM potassium chloride in 3% ammonium hydroxide. For fractions containing mono-and diphosphates, the pH was adjusted to 5 by adding 3% ammonium hydroxide. For the fraction containing triphosphates, the pH of the solution was adjusted to 5 by adding 10% formic acid. For each fraction, acid phosphatase (70 l) was added and the mixtures were incubated at 37°C for 5 h and then evaporated to 200 l with a TurboVap evaporator.
A Toso Haas DEAE column Administration of a single oral dose of ribavirin gave radioactivity levels of 3.5 g/ml and 50.5 g/g in RBC and liver, respectively. On the other hand, oral administration of viramidine gave radioactivity levels of 1.6 g/ml and 49.5 g/g in RBC and liver, respectively. Ribavirin administration gave a similar liver radioactivity level but twice the RBC radioactivity level of viramidine administration (Table 1) .
Ribavirin administration gave RBC radioactivity levels of 8.5 and 73.0 g/ml after administration of a single dose and multiple doses, respectively (Table 2) . It gave liver radioactivity levels of 8.3 and 16.6 g/g after administration of a single dose and multiple doses, respectively. On the other hand, viramidine administration gave RBC radioactivity levels of 4.4 and 34.3 g/ml after administration of a single dose and multiple doses, respectively. It gave liver radioactivity levels of 25.9 and 50.7 g/g after administration of a single dose and multiple doses, respectively. After administration of either a single dose or multiple doses, viramidine gave three times the liver radioactivity level of ribavirin. Both drugs exhibited twofold accumulation in monkey liver after administration of multiple doses. However, after administration of either a single dose or multiple doses, ribavirin gave twice the RBC radioactivity level of viramidine. Both drugs exhibited eightfold accumulation in monkey RBC after administration of multiple doses.
At 2 h following administration of a single dose of ribavirin or viramidine, TCONH 2 , ribavirin triphosphate (RTP), ribavirin monophosphate (RMP), and ribavirin represented the major radioactive components in rat RBC. Following administration of a single oral dose of ribavirin or viramidine, RMP and ribavirin were the predominated components in rat liver rather than RTP (Table 3) , probably owing to the instability of RTP at the presence of phosphatases in liver. After ribavirin administration, ribavirin, ribavirin diphosphate (RDP), and RTP were detected. Ribavirin, RDP, RTP, viramidine, viramidine monophosphate (VMP), viramidine diphosphate (VDP), viramidine triphosphate (VTP), and TCONH 2 were detected following oral administration of viramidine (Table 3 ). The total amount of ribavirin-related components after viramidine administration accounted for 68.1% of the total liver radioactivity (Table 3) , indicating rapid conversion of viramidine-related components to ribavirin-related components.
RTP represented the largest radioactive component in monkey RBC following administration of a single dose and multiple doses of ribavirin or viramidine (Table 4) . TCONH 2 was detected after administration of a single dose of ribavirin but not after administration of multiple doses. RDP was detected Table 4 ), suggesting that viramidine itself either cannot penetrate monkey RBC or that only a very small fraction of it entered RBC but was quickly converted to ribavirin-related components.
After administration of a single dose or multiple doses of ribavirin, RMP and ribavirin were the major components in monkey liver, rather than RTP and RDP (Table 4) , probably owing to the instability of phosphorylated derivatives of ribavirin in the presence of phosphatases in the liver. After administration of a single dose and multiple doses of viramidine, RMP, VMP, and TCONH 2 were the major radioactive components in the monkey liver ( Table 4 ). The total amount of ribavirin-related components (ribavirin plus RMP plus RDP plus RTP) accounted for 21.5% of the total radioactivity in the liver after administration of a single dose and 43.8% after administration of 10 daily oral doses ( (10) . In the present study, very high liver radioactivity concentrations were also obtained in rats and monkeys after oral administration of [ 14 C]ribavirin or [ 14 C]viramidine. Ribavirin and viramidine administration in rats gave similar drug levels in the liver. However, viramidine administration in monkeys gave three times the liver drug levels of ribavirin administration, indicating a better liver-targeting property of viramidine than ribavirin in monkeys.
Ribavirin can be phosphorylated to RMP (20) , RDP, and RTP (22) . RMP can also be quickly hydrolyzed to ribavirin, whereas this activity was negligible in RBC (15). Miller et al. (14) detected a high level of ribavirin in rat liver following oral administration of [ 3 H]ribavirin, followed by RMP, RDP, and RTP. In the present study, RMP rather than RTP is the predominated component in rat and monkey livers following oral administration of a single dose of ribavirin. This is in good agreement with the findings of Smee and Matthews (18) that upon removal of extracellular ribavirin, intracellular RTP was quickly degraded. After viramidine administration, viramidine was distributed into the rat liver, primarily as RMP and ribavirin with smaller amounts of RDP, RTP, viramidine, VMP, VDP, VTP, and TCONH 2 . These data indicate good penetration of the liver by viramidine, rapid conversion of viramidine to ribavirin, and phosphorylation of both viramidine and ribavirin in the liver. Viramidine administration and ribavirin administration gave similar levels of RTP (5 to 6%) in the rat liver, whereas ribavirin administration gave a higher level of RTP in the rat liver (5.4%) than in the monkey liver (2.7%). In rats, the total amount of ribavirin-related components (ribavirin plus RMP plus RDP and RTP) reached 68.1% at 2 h after administration, indicating rapid conversion of viramidine-re- lated components (viramidine plus VMP plus VDP plus VTP) to ribavirin-related components after absorption. In monkeys, however, the total amount of ribavirin-related components accounted for 21.5% of the total liver radioactivity after administration of a single dose and 43.8% of the liver radioactivity after administration of 10 daily doses. These data suggest that the total ribavirin-related components may account for most of the drug in the monkey liver following prolonged administration of viramidine. Canonico et al. (1) reported that monkey RBC accumulated the largest concentration of ribavirin, followed by human and rat RBC. Ribavirin is transported by the nitrobenzylthioinosine-sensitive nucleoside transporter into human RBC (5). Radioactivity levels in RBC were about twice the levels in the plasma of rats and 15 times the levels in the plasma of monkeys at 8 h following administration of [
14 C]ribavirin (3). In humans following oral administration of [ 14 C]ribavirin, the drug level in RBC was about 100-fold greater than the level in plasma (2). Laskin et al. (6) have shown that ribavirin can be taken up by human RBC and reach a steady-state concentration that exceeds the concentration in plasma by up to 60-fold (7) . In the present study, very high RBC radioactivity levels were also obtained in rats after administration of a single oral dose of ribavirin and in monkeys after oral administration of a single dose and multiple doses of ribavirin. Ribavirin administration gave higher RBC radioactivity concentrations than did viramidine administration in both rats and monkeys.
Page and Conners (15) reported that the ratio of mono-, di-, and triphosphates was 1:5:17 in RBC. However, no metabolic profile in the RBC of animals or humans following administration of ribavirin has been reported. In the present study, RTP represented the predominant radioactive component in rat and monkey RBC after ribavirin administration. This is in good agreement with findings in vitro (15) . Following administration of viramidine, RTP also was the predominant radioactive component in rat and monkey RBC. Smaller amounts of ribavirin, TCONH 2 , RMP, and RDP were also detected. However, viramidine, VMP, VDP, and VTP were not detected in RBC, suggesting that viramidine may be converted to ribavirin prior to entering RBC, that viramidine either cannot penetrate RBC, or that only a very small fraction of it entered RBC but was quickly converted to ribavirin-related components.
